Scholtz & Company LLC Raises Position in DexCom, Inc. $DXCM

Scholtz & Company LLC increased its stake in DexCom, Inc. (NASDAQ:DXCM) by 12.7% in the second quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 77,334 shares of the medical device company’s stock after buying an additional 8,686 shares during the quarter. DexCom comprises 2.6% of Scholtz & Company LLC’s portfolio, making the stock its 13th largest position. Scholtz & Company LLC’s holdings in DexCom were worth $5,208,000 as of its most recent filing with the SEC.

Several other hedge funds have also modified their holdings of the stock. Brighton Jones LLC raised its stake in shares of DexCom by 257.7% during the fourth quarter. Brighton Jones LLC now owns 16,582 shares of the medical device company’s stock valued at $1,290,000 after purchasing an additional 11,946 shares during the period. Integrated Wealth Concepts LLC lifted its position in shares of DexCom by 6.3% during the first quarter. Integrated Wealth Concepts LLC now owns 3,329 shares of the medical device company’s stock worth $227,000 after purchasing an additional 196 shares in the last quarter. Empowered Funds LLC boosted its stake in shares of DexCom by 5.4% in the first quarter. Empowered Funds LLC now owns 8,446 shares of the medical device company’s stock valued at $577,000 after purchasing an additional 436 shares during the period. Focus Partners Wealth boosted its stake in shares of DexCom by 13.2% in the first quarter. Focus Partners Wealth now owns 7,218 shares of the medical device company’s stock valued at $493,000 after purchasing an additional 841 shares during the period. Finally, NewEdge Advisors LLC grew its holdings in DexCom by 1.4% during the 2nd quarter. NewEdge Advisors LLC now owns 19,253 shares of the medical device company’s stock valued at $1,681,000 after purchasing an additional 258 shares in the last quarter. 97.75% of the stock is currently owned by hedge funds and other institutional investors.

Insider Activity at DexCom

In related news, Director Mark Foletta sold 4,000 shares of DexCom stock in a transaction dated Monday, June 15th. The stock was sold at an average price of $74.13, for a total value of $296,520.00. Following the completion of the transaction, the director directly owned 52,852 shares in the company, valued at approximately $3,917,918.76. This trade represents a 7.04% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Kevin R. Sayer sold 26,756 shares of the business’s stock in a transaction dated Monday, July 20th. The shares were sold at an average price of $76.32, for a total value of $2,042,017.92. Following the completion of the sale, the insider directly owned 328,970 shares of the company’s stock, valued at approximately $25,106,990.40. This represents a 7.52% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last three months, insiders sold 65,777 shares of company stock worth $4,950,714. 0.28% of the stock is currently owned by company insiders.

DexCom Trading Down 0.8%

DXCM opened at $83.88 on Thursday. The stock has a market capitalization of $31.65 billion, a PE ratio of 33.15, a P/E/G ratio of 1.42 and a beta of 1.42. The firm’s fifty day moving average price is $82.25 and its 200 day moving average price is $72.65. The company has a debt-to-equity ratio of 0.47, a current ratio of 1.73 and a quick ratio of 1.43. DexCom, Inc. has a 12-month low of $54.11 and a 12-month high of $92.59.

DexCom (NASDAQ:DXCM) last announced its quarterly earnings data on Thursday, July 30th. The medical device company reported $0.70 earnings per share for the quarter, topping the consensus estimate of $0.61 by $0.09. The company had revenue of $1.31 billion during the quarter, compared to analyst estimates of $1.29 billion. DexCom had a net margin of 20.12% and a return on equity of 35.94%. The firm’s revenue for the quarter was up 13.1% compared to the same quarter last year. During the same period last year, the business earned $0.48 EPS. As a group, research analysts expect that DexCom, Inc. will post 2.64 EPS for the current fiscal year.

Analyst Ratings Changes

Several research firms recently issued reports on DXCM. Stifel Nicolaus set a $95.00 price target on shares of DexCom and gave the stock a “buy” rating in a research note on Friday, July 31st. Piper Sandler reissued an “overweight” rating and issued a $95.00 price objective (up from $88.00) on shares of DexCom in a research report on Friday, July 31st. Wall Street Zen upgraded DexCom from a “hold” rating to a “buy” rating in a research note on Sunday. UBS Group set a $96.00 target price on DexCom and gave the stock a “buy” rating in a research report on Tuesday, July 28th. Finally, Citigroup reiterated a “buy” rating and issued a $88.00 price target (up from $84.00) on shares of DexCom in a research note on Friday, July 31st. Two investment analysts have rated the stock with a Strong Buy rating, twenty-one have assigned a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $88.71.

DexCom Company Profile

DexCom, Inc develops and commercializes continuous glucose monitoring (CGM) systems that measure glucose levels in real time. Its technology is designed to help people with diabetes monitor glucose trends and make more informed treatment and lifestyle decisions without relying solely on traditional fingerstick testing.

The company’s products include the Dexcom G7 and Dexcom G6 CGM systems, which use a small wearable sensor, transmitter or integrated sensor, and mobile applications to display glucose data.